Items Tagged ‘X-396’

August 29th, 2014

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising


Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer death in the U.S. and around the world. Up to […]

View full entry

Tags: alk, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, X-396